Currently, the HHS inspector general's website lists Juliet Hodgkins, principal deputy inspector general, as the ...
World-recognized brand Pfizer has agreed to a nearly $60 million financial agreement to settle claims that a wholly-owned ...
Recently, OIG’s Office of Audit Services released its latest report on providers’ compliance with the Hospital Price Transparency Rule (the HPT Rule). The HPT Rule requires hospitals to make public (1 ...
On December 17, 2024, the Department of Health & Human Services, Office of Inspector General (HHS-OIG) issued its second favorable advisory ...
In reviewing 24 accelerated FDA approvals, the Department of Health and Human Services (HHS) Office of Inspector General (OIG) uncovered issues with just two other nods: those for Sarepta ...
Last year, the HHS Office of Inspector General (OIG) confirmed its decision ... poses more than a low risk of fraud and abuse, and does not promote access to gene therapy care.
Vertex sued the HHS in July 2024 after the department ... According to the biotech’s lawsuit, the OIG claimed that Vertex’ fertility program “poses more than a low risk of fraud and abuse, and does ...
The Department of Health and Human Services and Drug Enforcement Administration published a series of rules Jan. 15 related to telemedicine prescribing of controlled substances, including a special ...
A new report from HHS' Office of Inspector General raises concerns about the FDA's accelerated approval process for drugs with weak supporting evidence, Bloomberg reported Jan. 14. The report ...
The HHS inspector general’s office detailed some of the behind-the-scenes action on the applications. In the case of Exondys, the director of the FDA’s drug division overruled the review team, which ...
“HHS-OIG and our law enforcement partners are committed ... Perwaiz was indicted on six counts of felony tax fraud. Perwaiz ended up pleading guilty to two of the counts and admitted to ...
The Department of Health and Human Services, Office of Inspector General (“OIG”) recently ... and associated risks related to healthcare fraud and abuse authorities. [1] See, e.g. AOs 20-02 ...